3.10 +0.16 (5.41%)
IMMU
Stock Details
Last Trade:3.10 Change:+0.16 (5.41%) Prev Close:2.94 Open: 2.96 Days Range:2.92 – 3.10 52 Week Range: 0.84 - 7.16 Volume:1735026 P/E: 6.46EPS:0.48
View AllRecent Alerts 02/09/10
Recent Alert on 02/02/10 at 8:35am
Immunomedics (IMMU) Reports Q2 EPS of $0.01
Immunomedics (IMMU) Reports Q2 EPS of $0.01
Immunomedics Inc. (Nasdaq: IMMU) reports Q2 EPS of $0.01, 1 cent better than the analyst estimate of $0.00. Revenue for the quarter was $5.1 million, which compares to the estimate of $5.92 million.
Recent Alert on 01/25/10 at 8:54am
Immunomedics (IMMU) Presents Data on Advanced Pancreatic Cancer Treatment (LLY)
Immunomedics (IMMU) Presents Data on Advanced Pancreatic Cancer Treatment (LLY)
Recent Alert on 01/25/10 at 8:54am
Immunomedics (IMMU) Presents Data on Advanced Pancreatic Cancer Treatment (LLY)
Immunomedics (IMMU) Presents Data on Advanced Pancreatic Cancer Treatment (LLY)
Recent Alert on 01/21/10 at 8:42am
Immunomedics (IMMU) Presented Results from Clivatuzumab Blood Test in Patients with Early-Stage Pancreatic Cancer
Immunomedics (IMMU) Presented Results from Clivatuzumab Blood Test in Patients with Early-Stage Pancreatic Cancer
Recent Alert on 01/21/10 at 8:42am
Immunomedics (IMMU) Presented Results from Clivatuzumab Blood Test in Patients with Early-Stage Pancreatic Cancer
Immunomedics (IMMU) Presented Results from Clivatuzumab Blood Test in Patients with Early-Stage Pancreatic Cancer
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 09/20/09 at 4:50pm
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers